


PD-Rx Pharmaceuticals, Inc.
Annual Report
2023





December 12, 2023

Dear Shareholders,

Fiscal Year 2023 ending June 30, 2023, was a year comparable to fiscal years of the past. It did not compare to last year's record sales and profits. This letter will serve as an update on the Company's operations and a report on the year-end financials. The review for PD-Rx Pharmaceuticals, Inc. is complete, and we have examined the results, making comparisons to last year and previous years to gain further insight. I would like to discuss management's thoughts regarding these outcomes.

I can report to you that sales for FY 2023 were \$21,271,614 down from last year's sales of \$28,715,224, but generally comparable with past year's sales. Total sales decreased by \$7,443,610. Commercial and governmental procurement and packaging sales were primarily the reason for the decrease in sales. The Company has a great deal of experience in this manner of pricing and sales with a historically successful track record. Two products that had significant packaging sales during FY 2022 were lost due to a change in the bidding and award process creating most of the decrease in sales. Point of care dispensing sales were slightly increased year over year and are back to pre-pandemic sales levels. Sales for FY 2023 were very comparable to sales in FY 2021 of \$21,602,200 and FY 2020 of \$21,025,546. Due to decreased sales, we recorded a loss of \$98,064 for FY 2023 as compared to a gain of \$3,033,984 in FY 2022. Selling, general and administrative expenses decreased by \$154,491, but remained elevated as compared to previous years due to increased pharmaceutical and regulatory personnel, the fluctuation of warehouse personnel due to Covid related employee procurement and training as well as additional sales and marketing personnel added during the fiscal year. These factors played a key role in the loss of income for FY 2023 of \$.06 per share.

Regarding our Balance Sheets, our net worth decreased this year to \$11,253,032 from \$11,351,806 in 2022. Our total assets decreased from \$13,222,561 in 2022 to \$12,950,236 in 2023. Cash and cash equivalents are increased in 2023 to \$6,833,516 as compared to 2022 at \$5,472,365, an increase of \$1.3 million. Total liabilities were lower this year, decreasing from \$1,870,755 in 2022 to \$1,697,204 in 2023. These are the quick view financial numbers that most shareholders are interested in. I encourage you to look further at: [:http://ftp.pdrx.com/docs/2023ReviewReport.pdf](http://ftp.pdrx.com/docs/2023ReviewReport.pdf) for complete financial information.

PD-Rx remains a leader in the repackaging industry, serving governmental, commercial and point of care pharmaceutical segments. We began pharmaceutical sales and repackaging in 1987. We continue to grow our sales division and increase our ability to repackage pharmaceutical products.



During FY 2023 we added an additional repackaging line, we made further infrastructure enhancements by adding a new roof over the 27,600 sq. ft. facility and new exterior paint and awnings. Our information technology department continues to develop new standards to facilitate the DSCSA (drug supply chain security act) which achieves interoperable, electronic tracing of products at the package level to identify and trace certain prescription drugs as they are distributed in the United States. In addition, we maintain our own proprietary Point of Care Dispensing Software which operates in the cloud. We have a great team of dedicated people who are committed to making PD-Rx a leader in the pharmaceutical industry. This is a shareholder owned company and I as well as all our management recognize the stewardship responsibility you have bestowed upon us.

Sincerely,

A handwritten signature in black ink, appearing to read 'Robert D. Holsey M.D.' with a flourish at the end.


Robert D. Holsey,
D.Ph., D.O. President
and Chief Executive
Officer




PD-RX
PHARMACEUTICALS
INCORPORATED®

| FINANCIAL HIGHLIGHTS | Year Ended June 30, | | | | | |
|------------------------------------|---------------------|---------------|---------------|---------------|---------------|---------------|
| | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
| Revenues | \$ 21,271,614 | \$ 28,715,224 | \$ 21,602,200 | \$ 21,025,546 | \$ 20,870,974 | \$ 24,967,418 |
| Operating Income (Loss) | (190,477) | 4,004,378 | 876,471 | (237,645) | (65,734) | 890,716 |
| Net Income (Loss) | (98,064) | 3,033,984 | 1,856,324 | (384,141) | (12,919) | 621,163 |
| Net Income (Loss) per share | \$ (0.06) | \$ 1.83 | \$ 1.08 | \$ (0.22) | \$ (0.01) | \$ 0.36 |

PD-Rx Annual Sales 2023



PD-Rx Annual Net Income 2023






Statement of Belief

- PD-Rx recognizes that we are a pharmaceutical service organization, and the continued success of the company is dependent on the day-to-day satisfaction of our customers.
 - We endorse a partnership of shared values-integrity, responsiveness, affordability, achievement and quality.
- We take the position that the long-term needs and expectations of our customers and PD-Rx are inseparable. We seek long terms business relationships based on our reputation of superior performance and customer service.
- We recognize that continuous improvements in technologies, automation, and operating concepts, are essential to the company's competitive position and health.

Corporate Overview

PD-Rx is a publicly traded corporation (Symbol: PDRX.PK). Beginning on June 30, 2023, our financial statements are reviewed each year to insure compliance with generally accepted accounting principles by a large local accounting firm. From inception until 2022 the Company's financial statements have been audited. The company maintains its own accounting and controller staff, along with Regulatory Affairs experts, Chief Pharmacist of Operations, Staffed Physician, FDA & DEA Compliance Officers, Quality Assurance Teams and Quality Control Production Teams. We maintain over 173 checks and balances in each production run, to make sure we provide the best quality products on the market. Representing PD-Rx is a team of over 24 sales experts throughout the United States, where PD-Rx maintains all 50 state boards of pharmacy and controlled substance distribution licenses. PD-Rx maintains a liability insurance policy of 2 Million in general coverage, 5 Million in Products Liabilities and a 10 Million-Dollar Umbrella Policy as additional insurance over and above the original manufacturer's liability coverage. The Board of Directors and key individual listed below bring with them over 240 years of experience in the pharmaceuticals industry and business relations. PD-Rx was original incorporated on September 1986 in the State of Oklahoma, and on February 5th, 1988, PD-Rx merged with Buckingham Venture Corp and re-incorporated in the State of Colorado, where they raised additional funds through a public offering and continued to raise additional capital for the next several years. PD-Rx Pharmaceuticals re-incorporated back into the State of Oklahoma on December 26th, 1990.



State of the Art Facility

- PD-Rx owns and operates a production and warehouse facility consisting of 27,600 square feet.
- The production facility has 4 separate clean rooms each with their own controlled environment.
- We provide 24 hour monitoring of relative humidity and temperature in our storage areas.
- Each production room is equipped with a Class 1 Micron Filtration Systems that can filter down to 3.0 Microns.
- The facility is equipped with a freestanding generator system that is capable of producing over 430 AMP of electricity, enough to power the whole plant without additional electricity from outside sources.
- The plant has been outfitted with the best security system available, consisting of motion detectors, glass break sensors, keypad entry, roll down steel doors, and internet networked cameras for 24 hours surveillance and security cages and vaults throughout the building.
- PD-Rx maintains its own staff of computer programmers and IT support staff, necessary to computerize our account on a national scale, and maintain the websites and internet portal systems for customer and representatives in the field.
-
- In 2009 PD-Rx completed the requirements the National Association of the Board of Pharmacy (NABP) to be Verified-Accredited Wholesale Distributors (**VAWD**) certified. The requirements require recertification every three years and PD-Rx maintained that certification. Our most recent VAWD recertification was completed in 2021. PD-Rx is accredited through September 2024.

Senior Management Team

Robert D. Holsey, D.O., D.Ph. (Age 71) - President, Chief Executive Officer, and Director

Dr. Holsey has served as a Director and President since the Company's inception. He is well suited for his role in the Company, drawing from both his education and his experience as a physician and a pharmacist. His combined years of experience in operating a successful pharmacy, his own private patient physician practice, and, in addition, his years of management experience in the repackaging/wholesale sector while at PD-Rx provides him the expertise necessary in carrying out his duties as President. Dr. Holsey graduated from the Altus Junior College and Central State University before entering pharmacy school. He was awarded a pharmacy degree in 1977 from the University of Oklahoma, School of Pharmacy, where he served as senior class president. As a Registered Pharmacist, he owned and operated a pharmacy in Binger, Oklahoma, prior to entering medical school in 1978. Dr. Holsey attended the Oklahoma State University College of Osteopathic Medicine and Surgery in Tulsa, Oklahoma. He was awarded a Doctor of Osteopathy degree in 1981 and completed his internship at Fort Worth Osteopathic Medical Center. From 1982 until 1986, Dr. Holsey was in private practice in Binger, Oklahoma. Dr. Holsey is currently active as a board certified family practice physician.

Jack L. McCall, II (Age 64) - Executive Vice President, Chief Operations Officer, Director, and Secretary

Mr. McCall has served as one of the Directors since September 1996 and as the Executive Vice President since December 1993. Previously with PD-Rx, Mr. McCall held the position of Vice President of Sales and Marketing and began his career with PD-Rx in May of 1989. Throughout his years of management experience Mr. McCall has excelled in understanding the pharmaceutical market trends and kept the Company ahead of the curve with his valuable intuition and market skills. He is a 1983 graduate of Southern Connecticut State University in New Haven, Connecticut with a Bachelor of Science Degree. He also attended the University of Massachusetts in Amherst for sales and product development training. Prior to joining PD-Rx, Mr. McCall spent 5 years employed with ParMed Pharmaceuticals in Niagara Falls, New York, known as one of the largest distributorships in the US. Mr. McCall has contract experience with national chain stores, major wholesalers, and state and federal contracts.

Robert L. Baker, CPA, (Age 75) - Chief Financial Officer, Director, and Treasurer

Mr. Baker has been a Director of the company since August, 1996. Previously, Mr. Baker has served PD-Rx since inception in a financial consulting capacity and has been involved in the preparation of various business plans for the Company as well as accounting system setup and organization for the repackaging operation. In 2012 Mr. Baker returned to daily responsibilities with PD-Rx. He is a Certified Public Accountant and previously served in various management

positions in the oil and gas industry. Mr. Baker has an accounting degree from Northwestern Oklahoma State University in Alva, Oklahoma.

Ben Silva, D.Ph. (Age 80) – Director of Pharmaceutical Operations

In 2000 Mr. Silva began employment with PD-Rx Pharmaceuticals Inc. of Oklahoma City as Director of Pharmaceutical Operations. In 1990, following five years of service as the Athletic Ticket Manager for the University of Oklahoma, Mr. Silva was employed by Sequoyah Healthcare Inc. and Neighbor Care Healthcare Inc. which were closed door pharmacies servicing nursing homes. From 1969 to 1985, Mr. Silva has served as a pharmacist and as a General Manager with both multi-site retail and clinic pharmacies. He has also owned his own retail pharmacy for eight years. Mr. Silva has been a Registered Pharmacist since 1969 and a Doctor of Pharmacy since 2001. He attended the University of Oklahoma and graduated from the O.U. College of Pharmacy in 1969.

Robert L. Surovec (75) Regulatory Affairs Compliance Officer

Mr. Surovec joined PD-Rx in 2008, serving as Regulatory Affairs Compliance Officer. He had previously been employed by the Drug Enforcement Administration (DEA) from 1971 to 2005. From 2000 to 2005 Mr. Surovec had served as Assistant Special Agent in Charge of the DEA Oklahoma City District Office. In 1996, Mr. Surovec was transferred to the DEA Headquarters, Washington, D.C. where he served as a Staff Coordinator with the Domestic Operations West Section and as an Inspector with the Office of Professional Responsibility (OPR). In 1998, Mr. Surovec was promoted to Section Chief of the Domestic Operations West Section. Mr. Surovec has previously served as a Special Agent with the DEA from 1971 to 1991, and in supervisory capacities in the DEA Houston Field Office. Mr. Surovec is a graduate of the University of Texas at Austin with a BA in Government.

Quality Production

The packaging operations at PD-Rx are completely automated with state of the art pharmaceutical repackaging / manufacturing equipment. Our automated production lines start with a bottle orientator and ends with the finished product bar coded and shrunk wrapped into 10 bottle tray packs. FDA guidelines require that a retention sample of each production run be kept on-site and made available to the FDA for inspection. PD-Rx photographs each product from a production runs and stores that photo with each lot number so assigned with every production run for future clarifications. Every production run is given a new lot number that is linked to the

retention sample and the original manufacturer and its pedigrees. Of the 4 production rooms, and 4 automated lines, each line is capable of manufacturing 1500-2000 bottles per hour. In addition to that we maintain 4 semi-automated production areas to handle smaller production runs.

Each container closure system (bottle and cap) used by PD-Rx will meet or exceed U.S. Pharmacopoeia Standards for moisture and light resistant barriers. Each bottle will be provided with a child resistant cap (CRC) and a tamper evident foil liner.



PD-Rx currently offers over 2600 prepackaged medications and over 2000 pass through items (i.e., creams, ointments, ophthalmics, otics, liquids & suspensions etc). Our injectable line is represented by over 700 different brand and generic medications.

PD-Rx will help you review drug cost and therapeutic substitutions. PD-Rx offers professional assistance by staffed pharmacists and physicians.

Quality Control

PD-Rx maintains over 173 stringent quality checks during each production run. Every order that is prepared for shipment is tracked and recorded. On the bottom of each 10 pack tray is a bar code that we scan and record the lot number and expiration date of the product when invoiced. From this information, PD-Rx will be able to run a Drug Distribution Data report also known as a DDD report. With this information in house, PD-Rx will be able to notify a clinic of a product recall within minutes. This report will be provided free of charge and is available at anytime. In



addition to this information, you will be able to go on line with www.pdrx.com and review your pedigree history simply by scanning the bar code on each bottle to track the complete flow of the products that you purchase from PD-Rx; we are 100 % pedigreed on all products offered to our customers since 2005.

Packaging

PD-Rx will provide you with an approved unit of use container closure system that meets or exceeds the U. S. Pharmacopeia Standards. The container closure system

starts with a White High Density Polyethylene (HDPE) bottles with a Child Resistant Cap (CRC) that is hermetically sealed with a tamper evident foil heat induction liner that has a center pull tab for easy opening. This type of foil liner will alert you if any tampering of medication has occurred.

Prescription Bottle: Shall consist of White High Density Polyethylene (HDPE) with a Child Resistant Cap (CRC) manufactured of White Density Polyethylene Cap and a High Density Polypropylene Inner Liner. Each bottle will be sealed with a Tamper Evident Foil liner that is hermetically sealed with a heat induction liner that has an Easy Open Seal center pull-tab.

Label Design: Each label will be made available with three removable tabs for dispensing and pharmacy log tracking capabilities. Each removable tab will identify the National Drug Code number, Product Description Strength, Expiration Date and Lot Number on each tab. Each Label will provide a set of so defined blank prescribing instructions both in English and Spanish, standard warning, Organoleptic markings, Bar Coded NDC #, and barcode Lot # and Expiration Dates.

All unit of use bottles are packaged in 10 pack trays and shrunk wrapped as a single unit for ease of storage and additional protection with tracking barcode on the bottom of each tray.

Pedigree Supply Chain

PD-Rx Pharmaceuticals, Inc. does its best to source all products from the manufacturers on a direct basis, and utilizes wholesalers and distributors around the US as secondary sources. The operations of PD-Rx are 100% pedigreed, and have been since 2005. PD-Rx maintains a Centralized Pedigree Repository, and you can review and pull up all of your pedigree information on line at our website www.pdrx.com under a customer log-in. You will be able to identify the manufacturer that we bought the product from, and the same information is available on every wholesaler or distributor in between that handled the product.

Drug Supply Chain Security

PD-Rx Pharmaceuticals, Inc. has always continued to assure compliance with all laws and new legislation relating to the prescription drug distribution chain. In 2013 the Drug Quality and Security Act was signed into law, part of which addressed drug supply chain security for the pharmaceutical supply distribution chain including PD-Rx. The Act establishes requirements which facilitate the tracing of prescription drug products throughout the supply process from the manufacturer to the smallest saleable unit. Implementation of the Act was phased in over approximately ten years. In November 2018, PD-Rx completed its compliance phase. This enables the Company to track each individualized serialized product.

Dispensing Platforms

PD-Rx offers a Manual Dispensing System for all customers at no additional cost. Our manual log system provides 10 recordkeeping labels to match the 10 bottle trays provided as a convenient handling package.

If the customer wishes to offer Patient Education Leaflets to their patients, this service is available on line at www.pdrx.com for both English and Spanish printed leaflets. The leaflets are printable from the PD-Rx website and are updated on our central server.

PD-Rx Net is a Web Based application that allows our customer's access through a web portal that can be reached from anywhere one can access a web browser.

The application is designed to track prescriptions filled at the point of care and print prescription labels for prescription that are filled onsite.

The application is capable of sending an electronic prescription a feature we call PD-Rx Link, and is Sure Script certified to their standards.



The application also offers a control substances reporting module call C-Report that meets the needs of state reporting requirements of individual states and their Prescription Drug Monitoring Programs requirements. With each prescription a Patient Education Leaflets is available in English and Spanish.

Computer Programmers and IT Support Staff

PD-Rx has finished its fourth rewrite of the PD-Rx Net program with new enhanced features, reports, and will be adding new functions to the platform this year for all of our customers that move over to the new versions.

PD-Rx has always written its own software, and has been doing so since 1986. We currently have three full time programmers and two full time IT & network support staff.

HIPAA and Network Security Profiles

Technology implementation of HIPAA covers three areas:

1. Physical Data Center Security
 - a. Access codes are required for entrance to data facility
 - b. Facility is monitored by closed circuit TV cameras to monitor and record internal and external building activities with an off-site hosted system.
 - c. Security system with motion sensors monitors the building 24 x 7.
 - d. Data backups are encrypted and sent off-site to a remote location.
 - e. Backups are verified regularly to assure recovery procedure

2. Network Security
 - a. Data is protected by redundant enterprise level firewalls.
 - b. All data transferred over the internet uses SSL with true 256-bit encryption.
 - c. All accounting and inventory systems use off-site backup systems through a third party provider.

3. Data Security
 - a. Separate individual user names and passwords.
 - b. User level access control (access can be restricted based on individual user accounts).

General and Contact Information

Shipping/Mailing Address:

PD-Rx Pharmaceuticals, Inc.

727 North Ann Arbor

Oklahoma City, OK 73127

LockBox Remittance Address:

PD-Rx Pharmaceuticals, Inc.

P.O. Box 960149

Oklahoma City, OK 73196

Local: (405) 942-3040

Fax: (405) 942-5471

Toll-Free: (800) 299-7379

Toll Free Fax: (800) 370-3556

Website: www.pdrx.com

For Order Entry, Online Tracking Shipments, Billing History, & Pedigree Report.

General E-mail: pdrx@pdrx.com

Hours of Operation: Monday through Friday

7:00 am to 5:00 pm (CST)

Corporate Information

Corporate Headquarters

727 North Ann Arbor
Oklahoma City, Oklahoma 73127
T - 1-405-942-3040
F - 1-405-942-5471

Common Stock

Stock Symbol: PDRX
OTC Bulletin Board

Stock Transfer Agent

Regular Mail

Computershare
P.O Box 43078
Providence, RI 02940-3078

Overnight/certified/registered delivery

Computershare
150 Royall Street, Suite 101
Canton, MA 02021

www.computershare.com

For all current Stock Certificate Holders please make sure that you keep Computershare updated as to your current address. If Computershare is unable to contact you as a Stock Certificate Holders, your property will be turned over to the state as unclaimed property. Shareholders Service Line is 1-800-962-4284

News and Press Information

Please visit our website at
www.pdrx.com

Independent Accountants

HSPG & Associates
Oklahoma City, Ok